Background
==========

In the past decade, the synthesis of iron-based magnetic nanoparticles has rapidly developed for fundamental biomedical applications, including bioseparation \[[@B1],[@B2]\], MRI contrast enhancement \[[@B3],[@B4]\], hyperthermia \[[@B5],[@B6]\], and drug delivery \[[@B7],[@B8]\]. For example, the Fe~3~O~4~nanoparticle has attracted great attentions for its potential theranostic applications \[[@B9]-[@B12]\]. As iron nanoparticles are administered to living subjects in most of their clinical applications, their *in vivo*biodistribution, clearance and biocompatibility must be determined for safe clinical usage. As such, *in vivo*studies of iron nanoparticles have made great progress in recent years.

*In vivo*studies of iron nanoparticles have mainly been performed using magnetic resonance imaging (MRI) \[[@B13]-[@B18]\]. MRI is the most widely used technique for imaging magnetic nanoparticles in small animals and humans. A major advantage of MRI is that it can be used to perform real-time imaging of the dynamic biodistribution and clearance of magnetic nanoparticles *in vivo*. However, MRI is still prohibitive to the common research laboratory. Therefore, fluorescence imaging techniques have been developed and applied in studies of magnetic nanoparticles. Iron nanoparticles have been labeled with fluorophores, such as FITC \[[@B19]-[@B21]\], rhodamine B \[[@B22],[@B23]\] and rhodamine 6G \[[@B18]\], resulting in the generation of bifunctional labeled nanoparticles, having both MRI and fluorescence imaging functions \[[@B24],[@B25]\]. Magnetic nanoparticles labeled with these conventional fluorophores (350-700 nm absorbing) have often been used to investigate the intracellular distribution of magnetic nanoparticles in cells \[[@B17],[@B18],[@B26]\]; however, these nanoparticles cannot be applied to *in vivo*imaging as the autofluorescence of tissues produce high background under excitation wavelengths less than 700 nm.

In recent years, near-infrared fluorescence (NIRF) imaging technology has been developed and progressively used to obtain biological functions of specific targets *in vitro*and in small animals \[[@B27]-[@B29]\]. NIR fluorophores work in the spectrum of 700 to 900 nm, which has a low absorption by tissue chromophores \[[@B30]\]. Therefore, NIRF imaging has minimal background interference. NIR fluorophores also have wide dynamic range and sensitivity, allowing NIRF imaging to obtain detectable signal intensity through several centimeters of tissue \[[@B31]-[@B33]\]. Based on these features, NIRF imaging has already been used to label nanoparticles and study their biodistribution, clearance and biocompatibility for *in vivo*biomedical applications. In a recent study, silica nanoparticles were labeled with DY776 and applied for *in vivo*bioimaging, biodistribution, clearance and toxicity analyses \[[@B34]\]. Furthermore, indocyanine green (ICG)-labeled calcium phosphate nanoparticles have been applied for imaging human breast cancer *in vivo*\[[@B35]\].

NIRF imaging has also been applied for the labeling of iron nanoparticles. Maxwell *et al*., used dextran-coated iron oxide nanoparticles (Feridex), covalently modified with Alexa Fluor 750, to label human hepatic stellate cells to monitor the engraftment process *in vivo*\[[@B36]\]. Furthermore, VivoTag 680-conjugated iron oxide particles have been intravenously injected into mice for imaging tumors \[[@B37]\]. Iron nanoparticles, labeled with Cy5.5 (excitation/emission (ex/em), 660/710 nm), have also been used as a MR contrast agent (CLIO) for sensoring the *in vivo*molecular environment surrounding the nanoparticles and tracing the *in vivo*biodistribution of CLIO in liver, spleen and kidneys \[[@B38]\]. Obviously, due to the excellent *in vivo*imaging performance of the NIR fluorophores, the NIRF-labeled iron nanoparticles provide a fine probe for the labeling of biomolecules or cells and *in vivo*imaging \[[@B39]-[@B42]\]. However, there is still a limited selection of available iron nanoparticles labeled with NIRF dyes with an optimal wavelength for imaging in the region of 800 nm, where tissue autofluorescence is minimal. Therefore, it is necessary to develop additional alternative NIRF-labeled iron nanoparticles in this area.

This study manufactured water-soluble 12-nm Fe~3~O~4~nanoparticles labeled with a new NIRF dye, IRDye800CW (Li-Cor Biosciences), which absorb and emit in higher wavelength light (ex/em, 774/789 nm), and investigated their applicability in cell labeling and *in vivo*imaging.

Results and discussions
=======================

Preparation of IRDy800CW-MNPs
-----------------------------

*M*-2, 3-dimercaptosuccinic acid (DMSA) has often been used as a coating on nanoparticles to improve their water solubility \[[@B43]-[@B46]\]. DMSA-coated nanoparticles have abundant carboxyls on their surface \[[@B47]-[@B49]\], which can be used to label nanoparticles with fluorophores \[[@B23]\]. Using these features of DMSA, we fabricated novel nanoparticles by firstly creating water-soluble DMSA-coated Fe~3~O~4~nanoparticles (MNPs), which were then reacted with ethyl-3, (3-di-methylaminopropyl carbodiimide) hydrochloride (EDC) to activate the surface carboxyl groups, following which we covalently crosslinked the NIRF dye, IRDy800CW, to the surface of the MNPs. The monodispersibility and size uniformity of MNPs and the IRDy800CW-labeled Fe~3~O~4~nanoparticles (IRDy800CW-MNPs) in their prepared water solution were analyzed by TEM. The results demonstrated that both nanoparticles had fine monodispersibility (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}). The average size of the nanoparticles was 11.0 ± 1.25 nm in diameter.

![**Characterization of IRDy800CW-MNPs**. (A) TEM image of MNPs. (B) TEM image of IRDy800CW-MNPs. (C) NIRF signal of nanoparticles. (D) Fluorescent spectrum of the nanoparticles. 1: IRDy800CW-MNPs; 2: MNPs. 3-4: The resuspended precipitate and supernatant of the IRDy800CW-MNPs solution after heat treatment and centrifugation. Abs: absorbance. Em: emission.](1477-3155-8-25-1){#F1}

The labeling effect of MNPs was evaluated by detecting the NIRF signal of the IRDy800CW-MNPs. In comparison with unlabeled MNPs, the IRDy800CW-MNPs had an intense NIRF signal (Figure [1C](#F1){ref-type="fig"}). The excitation and emission profiles indicated a peak excitation/emission wavelength of the IRDye800CW-MNPs at 775/788 nm. The Stokes shift for the IRDye800CW-MNPs was 13 nm (Figure [1D](#F1){ref-type="fig"}). The covalent linkage between IRDy800CW and the MNPs was confirmed by a heating experiment (see Methods), in which the IRDy800CW-MNPs retained the NIRF signal after heat treatment (Figure [1C](#F1){ref-type="fig"}). If the IRDy800CW was nonspecifically absorbed on the surface of MNPs, the heating treatment would destroy this, resulting in the NIRF signal being found in the supernatant. This result accords with the molecular mechanism that EDC is a carboxyl and amine-reactive cross-linker, which creates an amide bond between carboxyl and amino groups \[[@B50]\].

In this study, the DMSA coating was important for the water solubility and NIRF labeling of the MNPs. Normally, the uncoated iron oxide nanoparticle has a very low solubility due to its hydrophobic surface \[[@B51],[@B52]\]. The DMSA coating makes the surface hydrophilic and dispersible in water solutions \[[@B47]-[@B49],[@B53]-[@B59]\]. Furthermore, this coating can also improve the biocompatability of iron oxide nanoparticles. In a recent study, DMSA-coated Fe~2~O~3~nanoparticles were shown to have a low cytotoxicity \[[@B57]\], and have been used to label a variety of mammalian cells \[[@B47]-[@B49],[@B55]\]. Conversely, DMSA-coated iron nanoparticles have abundant carboxyl groups on their surface, which is useful for the covalent labeling of nanoparticles by fluorescent dyes \[[@B23]\].

In this study, MNPs were labeled with a newly developed NIRF dye, IRDye800CW, which has several advantages. Firstly, IRDye800CW is a reactive dye \[[@B60]\], which can be easily conjugated to MNPs. This labeling approach can be generalized to other DMSA-coated nanoparticles. Secondly, the excitation and emission of IRDye800CW are in the spectral region where tissue absorption, autofluorescence, and scattering are minimal (800 nm), allowing for the highest signal-to-noise ratio to be achieved in tissue imaging with this dye. For example, IRDye800 absorbs and emits at a higher wavelength light (ex/em, 774/804 nm) than Cy5 (ex/em, 646/664 nm) and therefore produced images with less background resulting from tissue autofluorescence \[[@B61]\]. A comparison of the *in vivo*fluorescent imaging performance of the epidermal growth factor (EGF)-conjugated Cy5.5 (ex/em, 660/710 nm) and IRDye800CW (ex/em, 785/830 nm) revealed that the EGF-IRDye800CW had a significantly reduced background, with an enhanced the tumor-to-background ratio (TBR) in comparison to EGF-Cy5.5 \[[@B62]\]. Thirdly, this dye is highly water-soluble and shows very low nonspecific binding to cellular components, while yielding a very high signal \[[@B60],[@B63]\]. Fourthly, the animal toxicity studies revealed that a single intravenous administration of IRDye800CW carboxylate, at doses of 1, 5, and 20 mg/kg, produced no pathological evidence of toxicity \[[@B60]\]. Furthermore, the animal studies revealed that IRDye800CW and its conjugates were capable of fine *in vivo*imaging in small animal models, such as the mouse \[[@B63]-[@B67]\]. IRDye800CW is also reported to be over 50 times brighter than ICG \[[@B68]\]. Based on these features, it is worth developing IRDye800CW-labeled iron nanoparticles as *in vivo*imaging probes with high signal-to-noise ratios.

Cell labeling with IRDy800CW-MNPs
---------------------------------

Cell labeling with iron nanoparticles is very important for biomedical applications \[[@B36]\]. Therefore, this study firstly investigated the applicability of IRDy800CW-MNPs in this field. The macrophage is commonly used as a cellular model to evaluate intravascularly administered agents, especially as it phagocytoses nanoparticles \[[@B10]\]. Therefore, this study employed the mouse macrophage RAW264.7 cell line to perform a cell-labeling assay. The cells were labeled with nanoparticles at various concentrations for 24 h. The cell labeling effect was evaluated by staining cells with Prussian blue and measuring the iron-loading of cells. The Prussian blue staining showed that the cells were effectively labeled by the MNPs and the IRDy800CW-MNPs (Figure [2](#F2){ref-type="fig"}). The blue-stained agglomerates of the iron nanoparticles in cells increased with the dose of nanoparticles in the cell culture media (Figure [2](#F2){ref-type="fig"}), which was in accordance with the results of the quantitative measurements of the relative iron-loading of cells using colorimetric and NIRF assays (Figure [3](#F3){ref-type="fig"}). In comparison, the NIRF assay reported the cellular iron-loading more sensitively than the normal colorimetric assay \[[@B69]-[@B72]\].

![**Prussian blue staining of cells**. The agglomerates of Fe~3~O~4~nanoparticles are stained in blue.](1477-3155-8-25-2){#F2}

![**Measurement of the relative iron-loading of cells**. (A) NIRF signal of cells labeled with IRDy800CW-MNPs at doses of 0, 20, 30, 40, 50, 60, 80 and 100 μg/ml (Column 1-8). Each dose contained 6 repeats (Row 1-6). Cells were washed with PBS before imaging. (B) Measurement of the relative iron-loading of cells (A) with colorimetric and NIRF approaches. Row 1-3: NIRF signals; Row 4-6: Colorimetric signals. (C) The intensity of colorimetric and NIRF signals (B). (D) The normalized intensity of colorimetric and NIRF signals (C). The signal of the nanoparticle-labeled cells was normalized to that of the negative control cell. The error bars represent mean and standard deviations of experiments performed in triplicate.](1477-3155-8-25-3){#F3}

The biocompatability of cells to the nanoparticles is also important to its applications. Therefore, we used an MTT assay to determine cell viability following treatment with the nanoparticles. The results revealed that the cell viability of RAW264.7 was not significantly (*p*\> 0.05) affected by the various doses of both MNPs and IRDy800CW-MNPs (Figure [4](#F4){ref-type="fig"}). In comparison with MNPs, the IRDy800CW-labeling did not bring toxicity to the MNPs. These results demonstrate that the IRDy800CW-MNPs have increased biocompatability. A dose of 30 μg/ml of the nanoparticles used in this MTT assay corresponds to the optimal blood concentration of a nanoparticle imaging agent, Combidexe, which has been intravascularly administered in humans at 2.6 mg Fe/kg body weight \[[@B10],[@B73]\].

![**Measurement of cell viability**. (A) NIRF signals of cells treated with MNPs (Column 1-3 and 10-12) and IRDy800CW-MNPs (Column 4-9) at doses of 0, 20, 30, 40, 50, 60, 80 and 100 μg/ml (From row 1-8) for 24 h. (B) NIRF signals of cells (A) after washing three times with PBS. (C) Quantitative measurement of cell viability by MTT assay. The error bars represent mean and standard deviations of experiments performed with 6 repeats.](1477-3155-8-25-4){#F4}

In vivo imaging with IRDy800CW-MNPs
-----------------------------------

Animal studies are indispensable to the clinical applications of nanoparticles. The biodistribution, metabolism, clearance and toxicity of nanoparticles must be examined in animal studies prior to their clinical application. In particular, these biological processes should be investigated in a dynamic and real-time form with living animals. In recent years, NIRF labeling has played an increasingly important role in *in vivo*studies \[[@B28]-[@B33]\]. Therefore, this study investigated the applicability of the IRDy800CW-MNPs in this field.

The *in vivo*studies were performed in a mouse model and employed a newly developed optical imaging instrument dedicated to small animal imaging, the Pearl Imager (LI-COR Biosciences) \[[@B74]\]. To obtain fine imaging effects, a naked mouse was used in this study. The mouse was first imaged prior to the administration of the nanoparticles to determine the value of the self-fluorescence background. Following this, the mouse was intravascularly administered IRDy800CW-MNPs at doses of 2 or 5 mg/kg body weight. The mouse was then discontinuously imaged at different time points. The real-time imaging of the mouse showed that the NIRF signal in the liver region and kidneys gradually intensified after injection of nanoparticles, reaching maximum levels at 6 h (Figure [5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}), thereby demonstrating a gradual enrichment of the IRDy800CW-MNPs in these regions. Following this, the NIRF signal in these regions gradually decreased, revealing a gradual clearance of the IRDy800CW-MNPs. These results demonstrate that the whole dynamic process of biodistribution and clearance of MNPs in the mouse model could be monitored and tracked by the IRDy800CW labels and the small animal NIRF-imaging system, Pearl Image.

![**NIRF imaging of a mouse administered IRDye800CW-MNPs at a dose of 2 mg/kg body weight**. The images are displayed in pseudo-color mode.](1477-3155-8-25-5){#F5}

![**NIRF imaging of a mouse administered the IRDy800CW-MNPs at a dose of 5 mg/kg body weight**. The images are displayed in pseudo-color mode.](1477-3155-8-25-6){#F6}

![**NIRF imaging of a mouse administered the IRDye800CW-MNPs at a dose of 5 mg/kg body weight**. The images are displayed in an overlay mode of light channel image and NIRF channel image.](1477-3155-8-25-7){#F7}

NIRF imaging of the mouse also clearly revealed that the intensity of signal in the liver region and kidneys was closely related to the dose of the intravenously injected IRDy800CW-MNPs. In comparison, the intensity of the NIRF signals in the liver and kidneys of the mouse injected with 2 mg/kg nanoparticles was much higher than that of the mouse injected with 5 mg/kg nanoparticles (Figure [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}). This signal/dose relationship may be used to investigate the metabolism efficiency of the different doses of nanoparticles.

To clarify the exact biodistribution of nanoparticles in different organs, the mouse was sacrificed after imaging for 5 days, and the organs, including the heart, lungs, liver, spleen and kidneys were isolated and their NIRF signal was measured. The results revealed that the IRDy800CW-MNPs mainly distributed in the liver, spleen and kidneys (Figure [8](#F8){ref-type="fig"}), with minimal distribution in the heart and lungs. This agrees with the results of whole body imaging. It can be found that the intense NIRF signal in the liver region, as measured by live-body imaging, actually comes from two organs, the liver and spleen. The liver is the largest organ in the body of a mouse and the spleen is far smaller, but the spleen is closely attached to the liver; therefore, it cannot be discerned from the liver in the live-body imaging. However, the organ imaging clearly revealed its importance in evaluating the biodistribution of the nanoparticles. Taken together, the individual NIRF imaging of organs is an important supplement to live-body imaging, as it revealed that the *in vivo*biodistribution and clearance of the MNPs mainly related to these three organs.

![**NIRF imaging of organs of a IRDy800CW-MNPs-injected mouse**. (A) Light images of heart, lung, liver, spleen and kidney of the mouse administered the IRDye800CW-MNPs. (B) NIRF images of the same organs.](1477-3155-8-25-8){#F8}

In previous studies, it was found that the magnetic nanoparticles were mainly distributed in the liver and spleen \[[@B13],[@B17],[@B18],[@B26],[@B75]-[@B77]\]. This pattern of biodistribution is independent of the routes of administration, such as intravenous injection \[[@B13]-[@B15],[@B18],[@B53],[@B75],[@B78],[@B79]\], intraperitoneal injection \[[@B26]\], intratracheally instillation \[[@B77]\], and inhalation \[[@B17]\]. These results are in agreement with our findings herein. The common highest distribution of various iron magnetic nanoparticles in liver and spleen closely relates to the reticulo-endothelial system (RES), also known as the mononuclear phagocytic system (MPS). The RES contains abundant phagocytic cells which can remove particulate materials from blood \[[@B80]\]. Therefore, the RES plays an important role in the biodistribution and clearance of nanoparticles *in vivo*\[[@B26],[@B76],[@B81],[@B82]\]. Furthermore, the liver and spleen are the major RES organs in body, with Kupffer cells and macrophages being their main RES members, respectively. It was reported that over 75% of the magnetic nanoparticles were promptly sequestered by the RES, particularly by the liver \[[@B83]\]. It was also reported that after 6 h following administration, approximately 55% iron nanoparticles were enriched in the liver by the RES \[[@B76]\]. TEM observation of the liver and spleen revealed that Kupffer cells contained an increasing number of progressively larger phagolysosomes containing magnetic nanoparticles 7 days after injection, and the macrophages in the spleen contained magnetic nanoparticles in lysosomes \[[@B79]\]. It was also reported that the USPIO accumulated in macrophages of the liver, spleen, lymph nodes and bone marrow \[[@B14],[@B73],[@B84],[@B85]\].

It was also reported that the magnetic nanoparticles were able to distribute in the kidneys, lungs, heart, brain, testes, uterus, ovary, bladder, thyroid, pancreas, and bone marrow \[[@B14]\]. However, the amount of nanoparticles distributed in these organs or tissues was far less than that in liver and spleen. This study revealed that the IRDy800CW-MNPs were also enriched in the kidneys. This may be related to the biological function of the kidneys, which is an important emunctory containing large a volume of blood undergoing filtration. The large difference in the NIRF intensity between the kidneys of mice injected with different doses of the IRDy800CW-MNPs (Figure [8](#F8){ref-type="fig"}) also demonstrated that the kidneys may play an important role in the biodistribution and clearance of iron nanoparticles.

The dose of the IRDy800CW-MNPs used in the *in vivo*imaging in this study is similar to those reported by other studies. The magnetic nanoparticles were reported to be intravascularly administered to mouse or rat at doses of 1 \[[@B15]\], 2 \[[@B15],[@B83]\], 3 \[[@B86]\], 5 \[[@B15],[@B87]\], and 10 mg Fe/kg body weight \[[@B76]\]. It was also reported that an intravascular nanoparticle imaging agent, Combidexe, was injected at 2.6 mg of Fe/kg body weight to humans for MRI \[[@B73]\].

This study did not measure physiological indexes and therefore cannot comment on any possible or potential effects of the IRDy800CW-MNPs to the health of mouse. However, careful observation of the mouse\'s behavior over the five days of *in vivo*imaging revealed that injection of the nanoparticles did not result in any observed adverse effects on activity, eating or drinking of the mouse. This implies that the IRDy800CW-MNPs may have better biocompatability to mice, which is the key small animal employed for the biomedical research of iron nanoparticles.

Conclusion
==========

This study manufactured water-soluble 12-nm DMSA-coated Fe~3~O~4~nanoparticle labeled with a NIRF dye, IRDye800CW, and investigated its applicability in cell labeling and living body imaging. The results demonstrate that the IRDye800CW-labeled Fe~3~O~4~nanoparticles effectively labeled a RAW264.7 cell, but did not significantly affect the cell viability. The animal studies demonstrate that the IRDye800CW-labeled Fe~3~O~4~nanoparticles could sensitively and in real-time monitor the whole dynamic process of the biodistribution and clearance of the Fe~3~O~4~nanoparticles in mouse. Therefore, IRDye800CW-labeled Fe~3~O~4~nanoparticles provide a new selection of available iron nanoparticles labeled with NIRF dyes with an optimal wavelength for imaging centered at 800 nm, which can be applied to *in vitro*cell labeling and *in vivo*imaging.

Methods
=======

Cells, animals and chemicals
----------------------------

The RAW264.7 cell line was purchased from the China Center for Type Culture Collection, Chinese Academy of Sciences (Shanghai, China). DMEM cell culture medium was purchased from Gibco, Invitrogen (CA, USA). The naked mouse (CByJ-Cg-Foxn1nu/J) was purchased from Model Animal Research Center of Nanjing, Nanjing University (Nanjing, China). The streptavidin-IRDye 800CW was purchased from Li-Cor Biosciences (Lincoln, NE, USA). The main chemicals, including EDC, HEPES, glutaraldehyde and paraformaldehyde, were purchased from Sigma Aldrich (MO, USA). Other chemicals, including potassium peroxydisulfate (K~2~S~2~O~8~), potassium ferrocyanide (KSCN), iron (III) chloride hexahydrate (FeCl~3~), and hydrochloric acid, were purchased from Sinopharm Chemical Reagent Co. Ltd (Shanghai, China).

Preparation of IRDy800CW-MNPs
-----------------------------

The water-soluble Fe~3~O~4~nanoparticles were synthesized under the following conditions. Firstly, 2.7 g of FeCl~3~•6H~2~O was dissolved in 50 ml of methanol, followed by the addition of 8.5 ml oleic acid. Then, a solution with 1.2 g of NaOH in 100 ml methanol was dropwise added into the solution under magnetic stirring conditions. The observed brown precipitate was washed with methanol 4-5 times and dried under vacuum overnight to remove all solvents. The obtained waxy iron-oleate was dissolved in 1-octadecanol at 70°C and reserved as a stable stock solution at room temperature. One milliliter of the stock solution (0.39 mM) was mixed with 4 ml 1-octadecanol and 0.5 ml oleic acid. The reaction mixture was heated to 320°C at a constant heating rate of 3.3°C/min, in a nitrogen atmosphere, and maintained at that temperature for 30 min. The resulting solution was cooled and precipitated by an addition of excess ethanol and centrifugation. The precipitate containing Fe~3~O~4~nanoparticles was washed 4-5 times with ethanol. To prepare water-soluble Fe~3~O~4~nanoparticles, 100 mg of above Fe~3~O~4~nanoparticles was dissolved in 10 ml chloroform, following which 50 μl triethylamine and 10 ml dimethyl sulfoxide (DMSO) containing 50 mg dispersed DMSA was added. The resulting solution was vortexed at 60°C for 12 h until a black precipitate was observed. The solution was subsequently centrifuged and the precipitate was carefully washed twice with ethanol and dissolved in 100 ml ethanol. To introduce more DMSA molecules onto the surface of Fe~3~O~4~nanoparticles, 50 μl triethylamine was added to the above ethanol solution containing Fe~3~O~4~nanoparticles, followed by the addition of a solution with 50 mg DMSA in 10 ml DMSO. The solution was again vortexed at 60°C for 12 h. The reaction solution was then centrifuged and the precipitate washed with ethanol 4-5 times carefully. The final MNPs were collected using a permanent magnet and transferred into 10 ml water.

The MNPs were labeled with NIR fluorophores by the following procedure. Six ml of nanoparticles (0.844 mg/ml Fe) were diluted into 24 ml and sonicated for 20 min. Following this, 10 mg EDC was added and sonicated for 40 min to activate the carboxyl groups on the surface of the nanoparticles. The solution was centrifuged at 12000 rpm for 10 min and the precipitate was resuspended in sterile deionized water. Then, 15 μl of Streptavidin-IRDye800CW was added to the resuspended nanoparticles and the nanoparticle solution was left on a rotator overnight. The nanoparticle solution was centrifuged at 12000 rpm for 10 min and the precipitate was washed 3 times with deionized water. Finally, the IRDye800CW-MNPs were resuspended in sterile deionized water.

The monodispersibility of MNPs and the IRDye800CW-MNPs was evaluated by TEM. Each of nanoparticles in the 30 μg/ml sample was added to a copper grid and observed with a JEM-2100 electron microscope (JEOL, Japan). The size of the nanoparticles was measured with Image Origin 6.1. The NIRF signal of the nanoparticles was detected with Odyssey Infrared Imaging System (Li-Cor). The fluorescent spectrum of the nanoparticles was measured using a Hitachi F-7000 Fluorescence Spectrophotometer. To verify that the IRDy800CW was covalently crosslinked to the nanoparticles and not by nonspecific absorption, the solution of NIRF-labeled nanoparticles was heated at 60°C for 15 min, and centrifuged to precipitate the nanoparticles. The supernatant and nanoparticles were collected separately, and the nanoparticles were resuspended in deionized water. The supernatants and the resuspended nanoparticles were detected with Odyssey Infrared Imaging System.

Cell labeling with IRDy800CW-MNPs
---------------------------------

To investigate the labeling of cells with nanoparticles, RAW264.7 cells were seeded into cell culture plates and cultured in DMEM supplemented with 10% fetal calf serum, penicillin (100 units/ml), streptomycin (100 μg/ml) and 10 mM HEPES in a humidified 5% CO~2~atmosphere at 37°C for 24 h. Then, the culture medium was discarded and the cells were cultured with fresh media containing nanoparticles at different doses for 24 h.

The labeling effects were evaluated by staining cells with Prussian blue and measurement of the iron-loading of cells. Prussian blue staining, which stains iron nanoparticles blue, was performed as previously described \[[@B47]-[@B49],[@B54]-[@B57]\]. The stained cells were observed with a light microscope (IX51, Olympus) and photographed using a Microscope Digital Camera (DP71, Olympus). The iron-loading of cells was measured with a common colorimetric assay, as previously described \[[@B69]-[@B72]\]. The iron-loading of the cells labeled by the IRDy800CW-MNPs was also evaluated by the NIRF signal. To measure the NIRF signal, cells were washed with PBS and lysed using SDS lysis buffer. The lysate was imaged and NIRF signal intensity was analyzed using the Odyssey Infrared Imaging System (Li-Cor).

The effect of labeling on the cell proliferation was evaluated by determining cell viability, which was assessed using a MTT assay, as reported elsewhere \[[@B82]-[@B84]\]. The cell viability of the nanoparticle-untreated cells (blank control) was defined as 100%, with the nanoparticle-treated cells being calculated as percentage of the control.

In vivo imaging with IRDy800CW-MNPs
-----------------------------------

Before injection of the IRDy800CW-MNPs, the mouse was imaged on a newly-developed infrared fluorescence imaging system, Pearl Image (Li-Cor). Subsequently, the mouse was anesthetized by ether inhalation and the IRDy800CW-MNPs were administered to the mouse by intravascular injection via the tail vein, at doses of 2 or 5 mg Fe/kg body weight. The mouse was housed under normal conditions and discontinuously imaged with Pearl Image at various time points. Just before each image acquisition, the mouse was anesthetized by ether inhalation. All images were captured at the same exciting intensity. After housing and imaging for 5 days following the injection of nanoparticles, the mouse was sacrificed by an overdose of anesthesia and the organs, including the heart, lungs, liver, spleen and kidneys were immediately collected. The organs were washed with PBS and imaged with a normal camera and Odyssey Infrared Imaging System (Li-Cor).
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MRI: Magnetic resonance imaging; NIRF: near infrared fluorescence; ICG: indocyanine green; PBS: Phosphate Buffer Solution; SDS: Sodium dodecyl sulfate; TEM: transmission electron microscopy; DMEM: Dulbecco\'s modified Eagle medium; CLIO: a form of MION (monocrystalline iron oxide nanoparticles) with cross-linked dextran coating: USPIO: dextran-coated SPIO (superparamagnetic iron oxide); EDC: 1-ethyl-3,(3-di-methylaminopropyl carbodiimide) hydrochloride; DMSA: *m*-2,3-dimercaptosuccinic acid; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
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